These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36510488)

  • 21. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.
    Dutta D; Nagendra L; Joshi A; Krishnasamy S; Sharma M; Parajuli N
    Obes Surg; 2024 May; 34(5):1653-1664. PubMed ID: 38502519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis.
    Zhang L; Hua Z; Fang Z; Wei J; Lin Y
    J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38874130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials.
    Lin Q; Xue Y; Zou H; Ruan Z; Ung COL; Hu H
    Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1461-1469. PubMed ID: 36180402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Discovery and Development of Liraglutide and Semaglutide.
    Knudsen LB; Lau J
    Front Endocrinol (Lausanne); 2019; 10():155. PubMed ID: 31031702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.
    Zhang R; Hou QC; Li BH; Deng L; Yang YM; Li TX; Yao XQ; Yang LL; Lin XL; Liao YQ; Wang L; Liu YP; Tan J; Wan ZW; Shuai P
    Front Endocrinol (Lausanne); 2023; 14():1132004. PubMed ID: 37455913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
    Taha MB; Yahya T; Satish P; Laird R; Agatston AS; Cainzos-Achirica M; Patel KV; Nasir K
    Curr Atheroscler Rep; 2022 Aug; 24(8):643-654. PubMed ID: 35624390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.
    Konwar M; Bose D; Jaiswal SK; Maurya MK; Ravi R
    Int J Clin Pract; 2022; 2022():1201977. PubMed ID: 35936066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GLP-1 agonists for people living with HIV and obesity, is there a potential?
    Zino L; Tack CJ; Richel O; Burger DM
    HIV Med; 2023 Oct; 24(10):1029-1034. PubMed ID: 37340561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
    Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Gao X; Hua X; Wang X; Xu W; Zhang Y; Shi C; Gu M
    Front Pharmacol; 2022; 13():935823. PubMed ID: 36188627
    [No Abstract]   [Full Text] [Related]  

  • 33. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 34. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.
    Andreadis P; Karagiannis T; Malandris K; Avgerinos I; Liakos A; Manolopoulos A; Bekiari E; Matthews DR; Tsapas A
    Diabetes Obes Metab; 2018 Sep; 20(9):2255-2263. PubMed ID: 29756388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
    Tan HC; Dampil OA; Marquez MM
    J ASEAN Fed Endocr Soc; 2022; 37(2):65-72. PubMed ID: 36578889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
    Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
    Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.
    Nuhoho S; Gupta J; Hansen BB; Fletcher-Louis M; Dang-Tan T; Paine A
    Diabetes Ther; 2019 Dec; 10(6):2183-2199. PubMed ID: 31599391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.
    Jiang Y; Liu J; Chen X; Yang W; Jia W; Wu J
    Adv Ther; 2021 Mar; 38(3):1470-1482. PubMed ID: 33582976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center.
    Hardin M; Adanse F; Schexnayder C; Malveaux J; Agbahiwe S
    Fed Pract; 2023 Dec; 40(Suppl 6):S24-S30. PubMed ID: 38812588
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.